The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.
Investing.com -- 诺和诺德公司(Novo Nordisk,NYSE:NVO)股价今日上涨2%,此前该公司宣布已满足与Catalent, Inc.(NYSE: CTLT)待完成交易的所有监管结束条件。这一进展表明,在著名生命科学投资公司Novo Holdings的私有化所有权下,这项战略举措即将完成。
Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...
The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said ...
Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...